Skip to content
lifestyle.ketodash.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cue Biopharma, Inc.
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
September 20, 2026
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 14, 2026
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
August 3, 2026
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
May 20, 2026
Cue Biopharma Announces $30 Million Private Placement
May 20, 2026
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
May 20, 2026
Cue Biopharma Announces 1-for-30 Reverse Stock Split
April 29, 2026
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
April 15, 2026
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement
April 8, 2026
Cue Biopharma Announces CEO Transition
March 27, 2026
1
2
Next Page
→